Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

Blood

Volumn 125, Issue 25, 2015, Pages 3868-3877

  Aydinok, Yesim ^a   Kattamis, Antonis ^b   Cappellini, M Domenica ^c   El Beshlawy, Amal ^d   Origa, Raffaella ^e   Elalfy, Mohsen ^f   Kilinç, Yurdanur ^g   Perrotta, Silverio ^h   Karakas, Zeynep ⁱ   Viprakasit, Vip ^j   Habr, Dany ^k   Constantinovici, Niculae ^k   Shen, Junwu ^k   Porter, John B ^l  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF MILAN   (Italy)

^d Cairo University   (Egypt)

^e UNIVERSITY OF CAGLIARI   (Italy)

^f Ain Shams University   (Egypt)

^g CUKUROVA UNIVERSITY   (Turkey)

^h IPoliclinico IIUniversità di Napoli   (Italy)

ⁱ ISTANBUL UNIVERSITY   (Turkey)

^j MAHIDOL UNIVERSITY   (Thailand)

^k NOVARTIS PHARMA AG   (Switzerland)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DEFERASIROX; DEFEROXAMINE; FERRITIN; IRON; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; SIDEROPHORE; TRIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ARTHRITIS; ARTICLE; CENTRAL NERVOUS SYSTEM INFECTION; CHILD; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE CONTROL; DISEASE SEVERITY; DRESS SYNDROME; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; FEVER; GEOMETRY; HEART ARRHYTHMIA; HEART FUNCTION; HEART HEMOSIDEROSIS; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IRON OVERLOAD; LIVER HEMOSIDEROSIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; TERATOMA; ADOLESCENT; ADVERSE EFFECTS; BLOOD TRANSFUSION; CHEMISTRY; CLINICAL TRIAL; DRUG EFFECTS; HEART; HEART MUSCLE; LIVER; YOUNG ADULT;

ADOLESCENT; ADULT; BENZOATES; BLOOD TRANSFUSION; CHILD; DEFEROXAMINE; FEMALE; HEART; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MALE; MYOCARDIUM; SIDEROPHORES; TRIAZOLES; YOUNG ADULT;

EID: 84935029971     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-07-586677     Document Type: Article

References (35)

1. Kirk P, Roughton M, Porter JB, et al. Cardiac T2∗magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120(20):1961-1968.
2. Carpenter JP, Roughton M, Pennell DJ; Myocardial Iron in Thalassemia (MINT) Investigators. International survey of T2∗cardiovascular magnetic resonance in β-thalassemia major. Haematologica. 2013;98(9):1368-1374.
3. Chouliaras GL, Kattamis A, Berdoukas V, Gotsis ED, Mavrogeni S, Ladis V. Cardiac magnetic resonance in transfusion dependent thalassaemia: assessment of iron load and relationship to left ventricular ejection fraction. Br J Haematol. 2010;151(4):397-401.
4. nd Revised Edition. 2008. Available at: www.thalassaemia.org.cy/wp-content/uploads/pdf/educational-programmes/Publications/Guidelines%20%282008%29/Thalassaemia%20Guidelines%20ENGLISH.pdf. Accessed May 11, 2015.
5. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in b-thalassemia. Blood. 2010;115(12):2364-2371.
6. Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement in myocardial T2∗over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica. 2011;96(1):48-54.
7. Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood. 2011;118(4):884-893.
8. Pathare A, Taher A, Daar S. Deferasirox (Exjade) significantly improves cardiac T2∗in heavily iron-overloaded patients with beta-thalassemia major. Ann Hematol. 2010;89(4):405-409.
9. Pennell DJ, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2∗in patients with β-thalassemia major. Haematologica. 2012;97(6):842-848.
10. Pennell DJ, Porter JB, Piga A, et al; CORDELIA study investigators. A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA). Blood. 2014;123(10):1447-1454.
11. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2∗cardiovascular magnetic resonance. Br J Haematol. 2004;127(3):348-355.
12. Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood. 2010;116(4):537-543.
13. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia. Blood. 2000;95(4):1229-1236.
14. Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients [published online ahead of print January 20, 2015]. Eur J Haematol. doi:10.1111/ejh.12507.
15. Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson. 2008;10:12.
16. Pepe A, Meloni A, Rossi G, et al. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy. J Cardiovasc Magn Reson. 2013;15:1.
17. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876-1884.
18. Lal A, Porter J, Sweeters N, et al. Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells Mol Dis. 2013;50(2):99-104.
19. Ladis V, Delaporta P, Kyriakopoulou D, Kattamis A. Combined chelation therapy with deferasirox and deferoxamine in transfusion-dependent patients with thalassemia [abstract]. Haematologica. 2010;95(suppl 2). Abstract 1818.
20. Grady RW, Galanello R, Randolph RE, Kleinert DA, Dessi C, Giardina PJ. Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine. Haematologica. 2013;98(1):129-135.
21. Cassinerio E, Orofino N, Roghi A, et al. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients. Blood Cells Mol Dis. 2014;53(3):164-167.
22. Origa R, Danjou F, Cossa S, et al. Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major. Br J Haematol. 2013;163(3):400-403.
23. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2∗) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171-2179.
24. St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105(2):855-861.
25. Carpenter JP, He T, Kirk P, et al. On T2∗magnetic resonance and cardiac iron. Circulation. 2011;123(14):1519-1528.
26. Westwood MA, Anderson LJ, Maceira AM, et al. Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron. J Magn Reson Imaging. 2007;25(6):1147-1151.
27. Noetzli LJ, Carson SM, Nord AS, Coates TD, Wood JC. Longitudinal analysis of heart and liver iron in thalassemia major. Blood. 2008;112(7):2973-2978.
28. Porter JB, Wood J, Olivieri N, et al. Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. J Cardiovasc Magn Reson. 2013;15:38.
29. Nichols-Vinueza DX, White MT, Powell AJ, Banka P, Neufeld EJ. MRI-guided iron assessment and oral chelator use improve iron status in thalassemia major patients: a six-year single center retrospective cohort study [abstract]. Blood. 2013;122(21). Abstract 563.
30. Chouliaras G, Berdoukas V, Ladis V, et al. Impact of magnetic resonance imaging on cardiac mortality in thalassemia major. J Magn Reson Imaging. 2011;34(1):56-59.
31. Lobo C, Angulo IL, Aparicio LR, Drelichman GI, Zanichelli MA, Cancado R; RELATH Investigators. Retrospective epidemiological study of Latin American patients with transfusional hemosiderosis: the first Latin American epidemiological study in iron overload - the RELATH study. Hematology. 2011;16(5):265-273.
32. Voskaridou E, Ladis V, Kattamis A, et al Greek Haemoglobinopathies Study Group. A national registry of haemoglobinopathies in Greece: deducted demographics, trends in mortality and affected births. Ann Hematol. 2012;91(9):1451-1458.
33. Porter JB, Taher AT, Aydinok Y, et al. Impact of liver iron overload on myocardial T2∗response in transfusion-dependent thalassemia major patients treated with deferasirox for up to 3 years [abstract]. Blood. 2013;122(21). Abstract 1016.
34. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738-3744.
35. Pennell DJ, Porter JB, Piga A, et al; CORDELIA study investigators. Sustained improvements in myocardial T2∗over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. Am J Hematol. 2015;90(2):91-96.